Skip to main
ICUI

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical is well-positioned for long-term success with its strong market position, diverse product portfolio, and strategic acquisitions. The company's solid financials, including a debt-to-equity ratio of 0.26 and a 5-year revenue growth rate of 24.45%, further support a positive outlook for investors. Additionally, ICU's focus on expanding their international presence and investing in new product development further strengthens their potential for growth in the future.

Bears say

ICU Medical is expected to face margin pressure in the coming years due to ongoing integration risks related to the recent acquisitions of Hospira and Smiths Medical, along with potential execution risks tied to the ongoing Smiths Medical integration. Additionally, the company's growth may be hindered by the completion of the U.S. plant consolidations and the shrinking of the competitive window before the replacement cycle accelerates in 2026. Furthermore, the potential separation of Vital Care could be accretive to revenue growth and margins, but the company continues to face risks related to the divestiture or sale of these products.

ICU Medical (ICUI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, ICU Medical (ICUI) has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $168.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $168.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.